Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

NCT05496036 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Merkel Cell Carcinoma

Interventions

DRUG: Pembrolizumab

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]